Pipamazine

Summary

Pipamazine (CHEMBL1909072) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 402 Da · C21H24ClN3OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909072
Name	Pipamazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6761
Molecular formula	C21H24ClN3OS
Molecular weight	402
InChIKey	OSJJYEUEJRVVOD-UHFFFAOYSA-N

SMILES: C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl

IUPAC name: 1-[3-(2-chlorophenothiazin-10-yl)propyl]piperidine-4-carboxamide

Also known as: Pipamazina, Pipamazine, pipamazine, PIPAMAZINE

Patent coverage: 503 distinct patent families (2,444 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 2,429 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M5, D(1A) dopamine receptor, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, Alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 2A.

Bioactivity

ChEMBL activities: 41 potent at pChembl ≥ 5 of 41 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2A	9.26	Ki	0.55	nM	CHEMBL_ACT_7736747
ADRA2B	9.11	Ki	0.79	nM	CHEMBL_ACT_7734536
ADRA1D	9.02	Ki	0.95	nM	CHEMBL_ACT_7734532
HRH1	8.94	Ki	1.15	nM	CHEMBL_ACT_7736637
DRD2	8.87	Ki	1.35	nM	CHEMBL_ACT_7734604
P15823	8.85	Ki	1.42	nM	CHEMBL_ACT_7734530
DRD3	8.8	Ki	1.59	nM	CHEMBL_ACT_7734606
ADRA2B	8.76	IC50	1.72	nM	CHEMBL_ACT_7734535
ADRA1D	8.71	IC50	1.94	nM	CHEMBL_ACT_7734531
HTR2A	8.71	IC50	1.94	nM	CHEMBL_ACT_7736746
P43140	8.68	Ki	2.08	nM	CHEMBL_ACT_7734528
P15823	8.59	IC50	2.56	nM	CHEMBL_ACT_7734529
DRD2	8.39	IC50	4.05	nM	CHEMBL_ACT_7734603
DRD3	8.33	IC50	4.67	nM	CHEMBL_ACT_7734605
P43140	8.29	IC50	5.14	nM	CHEMBL_ACT_7734527
ADRA2C	8.19	Ki	6.47	nM	CHEMBL_ACT_7734538
HRH1	8	IC50	9.94	nM	CHEMBL_ACT_7736636
HTR2C	7.96	Ki	11	nM	CHEMBL_ACT_7736751
DRD1	7.8	Ki	16	nM	CHEMBL_ACT_7734602
HTR2C	7.66	IC50	22	nM	CHEMBL_ACT_7736750
ADRA2A	7.6	Ki	25	nM	CHEMBL_ACT_7734534
HTR2B	7.51	Ki	31	nM	CHEMBL_ACT_7736749
DRD1	7.5	IC50	32	nM	CHEMBL_ACT_7734601
ADRA2C	7.35	IC50	45	nM	CHEMBL_ACT_7734537
SIGMAR1	7.32	Ki	48	nM	CHEMBL_ACT_7738769
HTR2B	7.31	IC50	49	nM	CHEMBL_ACT_7736748
HTR6	7.28	Ki	52	nM	CHEMBL_ACT_7738765
ADRA2A	7.18	IC50	66	nM	CHEMBL_ACT_7734533
CYP2D6	7	IC50	100	nM	CHEMBL_ACT_7734595
HTR6	6.95	IC50	112	nM	CHEMBL_ACT_7736756

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).